PVD

Flat Panel Display (FPD) Equipment Market Report 2023: Growing Demand for Consumer Electronics and Automotive Displays Underpins Sector

Retrieved on: 
Friday, May 26, 2023
PVD, E-procurement, Electronics, United States Census Bureau, COVID-19, FPD, CVD, Tablet, OLED, Lam Research, Flat, Growth, ADAS, Silicon, Glass, Flat-panel display, Television, Geography, Beauty salon, Printed circuit board

The flat panel display (FPD) equipment market is projected to grow at a CAGR of 3.35%, reaching US$8.763 billion in 2028 from US$6.956 billion in 2021.

Key Points: 
  • The flat panel display (FPD) equipment market is projected to grow at a CAGR of 3.35%, reaching US$8.763 billion in 2028 from US$6.956 billion in 2021.
  • The flat panel display (FPD) equipment market is driven by growing demand for consumer electronics and rising demand for large-screen and automotive displays.
  • Growing demand for consumer electronics- The increasing demand for smartphones, laptops, tablets, and other consumer electronic devices is driving the growth of the FPD equipment market.
  • The flat panel display (FPD) equipment market in North America is mainly driven by the high demand for consumer electronics, such as smartphones, laptops, and tablets.

Promising Developments Announced Ahead of 2023 ASCO Annual Meeting's Oral Presentations

Retrieved on: 
Friday, May 26, 2023
Optimism, Senior, Survival, Merck Group, Doctor of Philosophy, IMGN, GILD, MD, NUALS Arts and Literary Annual Meet, Patient, Sacituzumab govitecan, SVP, News, Business development, Brain, DPD, Hope, Mirvetuximab soravtansine, B-cell lymphoma, Gilead, Bortezomib, ONC, Randomness, TSX, Entrepreneurship, Safety, Axicabtagene ciloleucel, Gilead Sciences, Oncolytics Biotech, Neuro-Oncology (journal), CDK, Overalls, Cancer, Lung cancer, ImmunoGen, CBR, National Cancer Institute, Lymphoma, Daratumumab, ORR, Glioma, Pfizer, Progression-free survival, Paclitaxel, PVD, Dexamethasone, Fast track (FDA), ASCO, American Society of Clinical Oncology, Mantle cell lymphoma, Pelareorep, EHA, Multiple myeloma, Metastatic breast cancer, Society, Female, Breast cancer, Pharmaceutical industry, Birth control, Vaccine

VANCOUVER, B.C., May 26, 2023 /PRNewswire/ -- USA News Group  -  The world's biggest cancer conference is set to roll again at American Society of Clinical Oncology (ASCO) 2023, with in-person attendance back in full swing and already 40,000 people registered by mid-May. Much like other years, there's plenty of optimism ahead for the findings and intriguing data set to be presented, with oral presentations from some of the biotech sector's finest and up-and-comers, including from Gilead Sciences, Inc. (NASDAQ:GILD), ImmunoGen, Inc. (NASDAQ:IMGN), Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN), Legend Biotech Corporation (NASDAQ:LEGN), and Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC).

Key Points: 
  • According to the National Cancer Institute, HR+/HER2- is the most common cancer subtype, accounting for roughly 69% of all female breast cancer cases.
  • It's worth noting that Oncolytics has stated that it will also be presenting updated data from May 2023 at the oral presentation.
  • Additional data will be presented during the 2023 ASCO oral presentation.
  • Bringing in eight presentations to ASCO and EHA 2023 Annual Meetings, Legend Biotech Corporation (NASDAQ:LEGN) is set to deliver new and updated data from the CARTITUDE Clinical Development Program.

Promising Developments Announced Ahead of 2023 ASCO Annual Meeting's Oral Presentations

Retrieved on: 
Friday, May 26, 2023
Optimism, Senior, Survival, Merck Group, Doctor of Philosophy, IMGN, GILD, MD, NUALS Arts and Literary Annual Meet, Patient, Sacituzumab govitecan, SVP, News, Business development, Brain, DPD, Hope, Mirvetuximab soravtansine, B-cell lymphoma, Gilead, Bortezomib, ONC, Randomness, TSX, Entrepreneurship, Safety, Axicabtagene ciloleucel, Gilead Sciences, Oncolytics Biotech, Neuro-Oncology (journal), CDK, Overalls, Cancer, Lung cancer, ImmunoGen, CBR, National Cancer Institute, Lymphoma, Daratumumab, ORR, Glioma, Pfizer, Progression-free survival, Paclitaxel, PVD, Dexamethasone, Fast track (FDA), ASCO, American Society of Clinical Oncology, Mantle cell lymphoma, Pelareorep, EHA, Multiple myeloma, Metastatic breast cancer, Society, Female, Breast cancer, Pharmaceutical industry, Birth control, Vaccine

VANCOUVER, B.C., May 26, 2023 /PRNewswire/ -- USA News Group  -  The world's biggest cancer conference is set to roll again at American Society of Clinical Oncology (ASCO) 2023, with in-person attendance back in full swing and already 40,000 people registered by mid-May. Much like other years, there's plenty of optimism ahead for the findings and intriguing data set to be presented, with oral presentations from some of the biotech sector's finest and up-and-comers, including from Gilead Sciences, Inc. (NASDAQ:GILD), ImmunoGen, Inc. (NASDAQ:IMGN), Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN), Legend Biotech Corporation (NASDAQ:LEGN), and Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC).

Key Points: 
  • According to the National Cancer Institute, HR+/HER2- is the most common cancer subtype, accounting for roughly 69% of all female breast cancer cases.
  • It's worth noting that Oncolytics has stated that it will also be presenting updated data from May 2023 at the oral presentation.
  • Additional data will be presented during the 2023 ASCO oral presentation.
  • Bringing in eight presentations to ASCO and EHA 2023 Annual Meetings, Legend Biotech Corporation (NASDAQ:LEGN) is set to deliver new and updated data from the CARTITUDE Clinical Development Program.

AZIO Launches Tera 75 Keyboard, a Mechanical Keyboard With Interchangeable Design Materials - Now Live on Kickstarter

Retrieved on: 
Tuesday, May 16, 2023
Tera, Damascus steel, Kickstarter, Early Bird, DNA, PVD, ABS, OEM, RGB, Individual, CNC, Animation, Physical vapor deposition, Aluminium, 3D printing

LOS ANGELES, CA, May 17, 2023 - (ACN Newswire) - The Tera 75 is AZIO's next reiteration of mechanical keyboards made from a combination of world-class design and innovative technology created with users in mind.

Key Points: 
  • LOS ANGELES, CA, May 17, 2023 - (ACN Newswire) - The Tera 75 is AZIO's next reiteration of mechanical keyboards made from a combination of world-class design and innovative technology created with users in mind.
  • With a user-centric methodology, the Tera 75 was designed to give the user freedom in expressing their individuality with this keyboard as a palette to build their uniqueness.
  • Other features of the Tera 75 include:
    - Built-in triple layer foam and silicone dampers for and enhanced acoustical sensation while reducing vibration feedback.
  • - A variety of different backlight settings, including RGB colors and animation patterns
    The Tera 75 is now available on Kickstarter.

Legend Biotech to Demonstrate Progress in Advancing Potential Treatment Options for Patients with Multiple Myeloma at ASCO and EHA Annual Meetings

Retrieved on: 
Tuesday, May 16, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Abstract, DPD, Multiple myeloma, PVD, Dexamethasone, ASCO, Bortezomib, CAR, European Hematology Association, American Society of Clinical Oncology, Patient, EHA, Annual general meeting, Poster, Daratumumab, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Society, Food, BCMA, Pharmaceutical industry

“We are pleased that the latest data from the CARTITUDE-4 study will be officially presented at the meetings.

Key Points: 
  • “We are pleased that the latest data from the CARTITUDE-4 study will be officially presented at the meetings.
  • This was the study that showed — in front of the international community back in 2017 —promising results in heavily pretreated patients with multiple myeloma.
  • CARTITUDE-1 is a Phase 1b/2 study evaluating cilta-cel for the treatment of heavily pretreated patients with relapsed or refractory multiple myeloma.
  • This first-in-human, Phase 1 study evaluates LCAR-B38M CAR-T cells in patients with relapsed and refractory multiple myeloma.

Ideal Standard Unveils Novelties and Strategy at 'Together in Riyadh' Event in Saudi Arabia

Retrieved on: 
Monday, March 20, 2023
Ideal Standard, Collection, Ceramic, PVD, Culture, Marketing, Qiddiya, NEOM, Interior design, Renewable energy

Over 200 guests attended Together in Riyadh,' including industry leaders, design enthusiasts, and Ideal Standard distributor Al Ghamdi Company.

Key Points: 
  • Over 200 guests attended Together in Riyadh,' including industry leaders, design enthusiasts, and Ideal Standard distributor Al Ghamdi Company.
  • Ahmed Hafez, Chief Executive Officer at Ideal Standard MENA, said: "The 'Together in Riyadh' event is a testament to our commitment to the Saudi market.
  • Our innovative products and our commitment to quality make Ideal Standard the perfect partner for wholesale and ambitious projects planned for Saudi Arabia."
  • At the event, Ideal Standard showcased its faucets with state-of-the-art technology, including the FirmaFlow+ cartridge and LightMove technology.

Ideal Standard Unveils Novelties and Strategy at 'Together in Riyadh' Event in Saudi Arabia

Retrieved on: 
Monday, March 20, 2023
Ideal Standard, Collection, Ceramic, PVD, Culture, Marketing, Qiddiya, NEOM, Interior design, Renewable energy

Over 200 guests attended Together in Riyadh,' including industry leaders, design enthusiasts, and Ideal Standard distributor Al Ghamdi Company.

Key Points: 
  • Over 200 guests attended Together in Riyadh,' including industry leaders, design enthusiasts, and Ideal Standard distributor Al Ghamdi Company.
  • Ahmed Hafez, Chief Executive Officer at Ideal Standard MENA, said: "The 'Together in Riyadh' event is a testament to our commitment to the Saudi market.
  • Our innovative products and our commitment to quality make Ideal Standard the perfect partner for wholesale and ambitious projects planned for Saudi Arabia."
  • At the event, Ideal Standard showcased its faucets with state-of-the-art technology, including the FirmaFlow+ cartridge and LightMove technology.

Physical vapor deposition (PVD) equipment market size is set to grow by USD 4,255.71 million from 2022-2027; Growth driven by growing demand for electronic devices -Technavio

Retrieved on: 
Monday, March 13, 2023
Pressure, IP, PVD, Geography, USD, Risk, Challenge, Miniaturization, Temperature, Terrorism, Growth, Automation, ICS, Specialization, Video game, Surface finishing, COVID-19

NEW YORK, March 13, 2023 /PRNewswire/ -- According to Technavio, the global physical vapor deposition (PVD) equipment market size is estimated to grow by USD 4,255.71 million from 2022 to 2027.

Key Points: 
  • NEW YORK, March 13, 2023 /PRNewswire/ -- According to Technavio, the global physical vapor deposition (PVD) equipment market size is estimated to grow by USD 4,255.71 million from 2022 to 2027.
  • Additionally, the increasing miniaturization of electronic components and the need for high-performance and durable products are driving the demand for PVD systems.
  • Technavio has segmented the market based on type (sputtering deposition and evaporation deposition), and application (microelectronics, medical devices and equipment, solar products, and others).
  • The report provides actionable insights and estimates the contribution of all regions to the growth of the global physical vapor deposition (PVD) equipment market.

Acquisition Completed

Retrieved on: 
Wednesday, March 1, 2023
Sondrio, Clothing, DMC, Acquisition, PVD, Trento, Management, Retail

Oerlikon Successfully Closed Acquisition of Riri; Takes Leadership Position in Luxury Metalware

Key Points: 
  • Oerlikon Successfully Closed Acquisition of Riri; Takes Leadership Position in Luxury Metalware
    Pfaeffikon, Schwyz, Switzerland – March 1, 2023 – Oerlikon has successfully closed the acquisition of Riri, following the signing of the agreement announced on December 16, 2022.
  • This deal is the logical strategic next step to complement Oerlikon’s acquisition of Coeurdor in 2021.
  • This acquisition expands Oerlikon’s foothold in the luxury market and together creates a leading platform in luxury metalware.
  • “The acquisition leverages Oerlikon’s core PVD coating competencies into applications in the luxury market,” said Michael Suess, Executive Chairman.

Ideal Standard unveils new design-led Gusto kitchen tap collection

Retrieved on: 
Tuesday, February 28, 2023
Knowledge, Gold, Ideal Standard, Installation, Collection, Scratch, PVD, Temperature, Ludovica, Gusto, EU

DUBAI, UAE, Feb. 28, 2023 /PRNewswire/ -- Ideal Standard has launched its new Gusto tap range, designed specifically for kitchens.

Key Points: 
  • DUBAI, UAE, Feb. 28, 2023 /PRNewswire/ -- Ideal Standard has launched its new Gusto tap range, designed specifically for kitchens.
  • Gusto marks Ideal Standard's latest expansion into the kitchen sector, offering a versatile, practical and premium solution to its growing portfolio.
  • The Gusto collection has been developed and designed with immense attention to detail, supported by over 100 years of knowledge and innovation in brassware manufacturing, which has placed Ideal Standard firmly at the forefront of the bathroom and washroom sector.
  • The range is available in two different styles, Gusto Round, a classic and elegant curved design and Gusto Square a bolder, contemporary square shape.